Molecular markers and targets in melanoma
C Teixido, P Castillo, C Martinez-Vila, A Arance, L Alos - Cells, 2021 - mdpi.com
Melanoma develops as a result of several genetic alterations, with UV radiation often acting
as a mutagenic risk factor. Deep knowledge of the molecular signaling pathways of different …
as a mutagenic risk factor. Deep knowledge of the molecular signaling pathways of different …
[HTML][HTML] Metastatic uveal melanoma: The final frontier
ES Rantala, MM Hernberg, S Piperno-Neumann… - Progress in Retinal and …, 2022 - Elsevier
Abstract Treatment of primary intraocular uveal melanoma has developed considerably, its
driver genes are largely unraveled, and the ways to assess its risk for metastases are very …
driver genes are largely unraveled, and the ways to assess its risk for metastases are very …
Efficacy of MEK inhibition in patients with histiocytic neoplasms
EL Diamond, BH Durham, GA Ulaner, E Drill, J Buthorn… - Nature, 2019 - nature.com
Histiocytic neoplasms are a heterogeneous group of clonal haematopoietic disorders that
are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway …
are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway …
Treatment of uveal melanoma: where are we now?
J Yang, DK Manson, BP Marr… - … advances in medical …, 2018 - journals.sagepub.com
Uveal melanoma, a rare subset of melanoma, is the most common primary intraocular
malignancy in adults. Despite effective primary therapy, nearly 50% of patients will develop …
malignancy in adults. Despite effective primary therapy, nearly 50% of patients will develop …
Targeting RAS–ERK signalling in cancer: promises and challenges
AA Samatar, PI Poulikakos - Nature reviews Drug discovery, 2014 - nature.com
Abstract The RAS–RAF–MEK–ERK signalling pathway is hyperactivated in a high
percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS …
percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS …
Overcoming immune evasion in melanoma
Melanoma is the most aggressive and dangerous form of skin cancer that develops from
transformed melanocytes. It is crucial to identify melanoma at its early stages, in situ, as it is …
transformed melanocytes. It is crucial to identify melanoma at its early stages, in situ, as it is …
Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine
AJ Aguirre, JA Nowak, ND Camarda, RA Moffitt… - Cancer discovery, 2018 - AACR
Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but
molecular characterization is not yet standard in clinical care. We implemented a biopsy …
molecular characterization is not yet standard in clinical care. We implemented a biopsy …
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …
Metastatic disease from uveal melanoma: treatment options and future prospects
RD Carvajal, GK Schwartz, T Tezel, B Marr… - British Journal of …, 2017 - bjo.bmj.com
Uveal melanoma represents∼ 85% of all ocular melanomas and up to 50% of patients
develop metastatic disease. Metastases are most frequently localised to the liver and, as few …
develop metastatic disease. Metastases are most frequently localised to the liver and, as few …
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
RB Corcoran, CE Atreya, GS Falchook… - Journal of clinical …, 2015 - ascopubs.org
Purpose To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a
selective MEK inhibitor, in patients with BRAF V600–mutant metastatic colorectal cancer …
selective MEK inhibitor, in patients with BRAF V600–mutant metastatic colorectal cancer …